Eli Lilly Return on Investment 2010-2022 | LLY

Current and historical return on investment (ROI) values for Eli Lilly (LLY) over the last 10 years.
Eli Lilly ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-06-30 $7.41B $23.35B 30.90%
2022-03-31 $7.61B $24.62B 32.36%
2021-12-31 $6.36B $24.50B 27.43%
2021-09-30 $6.43B $23.48B 28.40%
2021-06-30 $5.83B $21.40B 26.36%
2021-03-31 $5.62B $23.30B 26.03%
2020-12-31 $6.06B $22.41B 30.19%
2020-09-30 $5.47B $21.33B 29.40%
2020-06-30 $5.62B $19.34B 32.04%
2020-03-31 $5.92B $17.18B 35.14%
2019-12-31 $4.97B $16.52B 29.97%
2019-09-30 $4.47B $17.13B 25.57%
2019-06-30 $4.39B $16.58B 22.30%
2019-03-31 $2.88B $16.18B 13.91%
2018-12-31 $3.53B $20.11B 15.58%
2018-09-30 $2.91B $25.83B 12.64%
2018-06-30 $2.11B $20.79B 9.26%
2018-03-31 $3.32B $23.98B 14.04%
2017-12-31 $2.00B $21.61B 8.69%
2017-09-30 $2.40B $24.89B 10.33%
2017-06-30 $2.81B $24.04B 12.13%
2017-03-31 $2.53B $21.74B 11.01%
2016-12-31 $3.26B $22.45B 14.09%
2016-09-30 $2.91B $24.32B 12.56%
2016-06-30 $2.93B $23.34B 12.77%
2016-03-31 $2.88B $22.51B 12.65%
2015-12-31 $2.69B $22.56B 11.83%
2015-09-30 $2.67B $23.31B 11.99%
2015-06-30 $2.31B $22.69B 10.40%
2015-03-31 $2.32B $22.36B 10.38%
2014-12-31 $2.66B $20.72B 11.74%
2014-09-30 $3.23B $22.98B 14.09%
2014-06-30 $4.18B $23.30B 18.58%
2014-03-31 $4.79B $23.60B 22.26%
2013-12-31 $5.37B $21.84B 26.23%
2013-09-30 $5.50B $21.16B 27.39%
2013-06-30 $5.10B $19.53B 25.25%
2013-03-31 $4.80B $19.39B 23.67%
2012-12-31 $4.73B $20.29B 23.12%
2012-09-30 $4.72B $21.57B 23.40%
2012-06-30 $5.16B $19.81B 25.95%
2012-03-31 $5.55B $20.23B 28.02%
2011-12-31 $5.53B $19.00B 28.33%
2011-09-30 $5.87B $20.51B 30.02%
2011-06-30 $6.04B $19.48B 31.32%
2011-03-31 $6.23B $19.07B 33.35%
2010-12-31 $6.53B $19.18B 35.89%
2010-09-30 $5.75B $19.39B 32.94%
2010-06-30 $5.68B $17.10B 33.87%
2010-03-31 $5.49B $17.12B 33.70%
2009-12-31 $5.59B $16.16B 35.65%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $287.922B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84
Novartis AG (NVS) Switzerland $192.828B 14.22